nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA2A—epilepsy syndrome	0.543	1	CbGaD
Apraclonidine—Lofexidine—ADRA2A—epilepsy syndrome	0.0022	0.359	CrCbGaD
Apraclonidine—Brimonidine—ADRA2A—epilepsy syndrome	0.00142	0.231	CrCbGaD
Apraclonidine—Tizanidine—ADRA2A—epilepsy syndrome	0.0013	0.212	CrCbGaD
Apraclonidine—Clonidine—ADRA2A—epilepsy syndrome	0.000634	0.103	CrCbGaD
Apraclonidine—Clonidine—CYP2D6—epilepsy syndrome	0.00034	0.0554	CrCbGaD
Apraclonidine—Clonidine—ABCB1—epilepsy syndrome	0.000243	0.0395	CrCbGaD
Apraclonidine—ADRA1A—hindbrain—epilepsy syndrome	0.000202	0.103	CbGeAlD
Apraclonidine—Conjunctivitis—Topiramate—epilepsy syndrome	0.00016	0.000524	CcSEcCtD
Apraclonidine—Dermatitis—Propofol—epilepsy syndrome	0.000159	0.000522	CcSEcCtD
Apraclonidine—Headache—Propofol—epilepsy syndrome	0.000158	0.000519	CcSEcCtD
Apraclonidine—Mediastinal disorder—Gabapentin—epilepsy syndrome	0.000158	0.000519	CcSEcCtD
Apraclonidine—Hypersensitivity—Zonisamide—epilepsy syndrome	0.000158	0.000518	CcSEcCtD
Apraclonidine—Vomiting—Midazolam—epilepsy syndrome	0.000157	0.000516	CcSEcCtD
Apraclonidine—Diarrhoea—Vigabatrin—epilepsy syndrome	0.000157	0.000516	CcSEcCtD
Apraclonidine—Asthenia—Felbamate—epilepsy syndrome	0.000157	0.000515	CcSEcCtD
Apraclonidine—Vision blurred—Pregabalin—epilepsy syndrome	0.000157	0.000515	CcSEcCtD
Apraclonidine—Chest pain—Valproic Acid—epilepsy syndrome	0.000157	0.000514	CcSEcCtD
Apraclonidine—Myalgia—Valproic Acid—epilepsy syndrome	0.000157	0.000514	CcSEcCtD
Apraclonidine—Feeling abnormal—Lamotrigine—epilepsy syndrome	0.000156	0.000511	CcSEcCtD
Apraclonidine—Dizziness—Fosphenytoin—epilepsy syndrome	0.000156	0.000511	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	0.000155	0.000511	CcSEcCtD
Apraclonidine—Dermatitis—Midazolam—epilepsy syndrome	0.000155	0.000511	CcSEcCtD
Apraclonidine—Vomiting—Levetiracetam—epilepsy syndrome	0.000155	0.000509	CcSEcCtD
Apraclonidine—Discomfort—Valproic Acid—epilepsy syndrome	0.000155	0.000508	CcSEcCtD
Apraclonidine—Headache—Midazolam—epilepsy syndrome	0.000155	0.000508	CcSEcCtD
Apraclonidine—Pruritus—Felbamate—epilepsy syndrome	0.000155	0.000508	CcSEcCtD
Apraclonidine—Abdominal pain—Carbamazepine—epilepsy syndrome	0.000154	0.000508	CcSEcCtD
Apraclonidine—Diarrhoea—Diazepam—epilepsy syndrome	0.000154	0.000508	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	0.000154	0.000508	CcSEcCtD
Apraclonidine—Ill-defined disorder—Pregabalin—epilepsy syndrome	0.000154	0.000507	CcSEcCtD
Apraclonidine—Dermatitis—Levetiracetam—epilepsy syndrome	0.000154	0.000505	CcSEcCtD
Apraclonidine—Asthenia—Zonisamide—epilepsy syndrome	0.000153	0.000504	CcSEcCtD
Apraclonidine—Mental disorder—Gabapentin—epilepsy syndrome	0.000153	0.000504	CcSEcCtD
Apraclonidine—Dry mouth—Valproic Acid—epilepsy syndrome	0.000153	0.000503	CcSEcCtD
Apraclonidine—Headache—Levetiracetam—epilepsy syndrome	0.000153	0.000502	CcSEcCtD
Apraclonidine—Erythema—Gabapentin—epilepsy syndrome	0.000152	0.000501	CcSEcCtD
Apraclonidine—Hypersensitivity—Clonazepam—epilepsy syndrome	0.000152	0.000499	CcSEcCtD
Apraclonidine—Dizziness—Vigabatrin—epilepsy syndrome	0.000152	0.000498	CcSEcCtD
Apraclonidine—Pruritus—Zonisamide—epilepsy syndrome	0.000151	0.000497	CcSEcCtD
Apraclonidine—Hypersensitivity—Phenytoin—epilepsy syndrome	0.000151	0.000496	CcSEcCtD
Apraclonidine—Oedema—Valproic Acid—epilepsy syndrome	0.00015	0.000493	CcSEcCtD
Apraclonidine—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	0.00015	0.000493	CcSEcCtD
Apraclonidine—Bradycardia—Topiramate—epilepsy syndrome	0.00015	0.000493	CcSEcCtD
Apraclonidine—Malaise—Pregabalin—epilepsy syndrome	0.00015	0.000493	CcSEcCtD
Apraclonidine—Nausea—Propofol—epilepsy syndrome	0.00015	0.000492	CcSEcCtD
Apraclonidine—Tension—Gabapentin—epilepsy syndrome	0.00015	0.000492	CcSEcCtD
Apraclonidine—Vomiting—Fosphenytoin—epilepsy syndrome	0.00015	0.000491	CcSEcCtD
Apraclonidine—Diarrhoea—Felbamate—epilepsy syndrome	0.000149	0.000491	CcSEcCtD
Apraclonidine—Abdominal pain—Lamotrigine—epilepsy syndrome	0.000149	0.000491	CcSEcCtD
Apraclonidine—Dysgeusia—Gabapentin—epilepsy syndrome	0.000149	0.000491	CcSEcCtD
Apraclonidine—Dizziness—Diazepam—epilepsy syndrome	0.000149	0.000491	CcSEcCtD
Apraclonidine—Infection—Valproic Acid—epilepsy syndrome	0.000149	0.00049	CcSEcCtD
Apraclonidine—Syncope—Pregabalin—epilepsy syndrome	0.000149	0.00049	CcSEcCtD
Apraclonidine—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000148	0.000487	CcSEcCtD
Apraclonidine—Nervousness—Gabapentin—epilepsy syndrome	0.000148	0.000487	CcSEcCtD
Apraclonidine—Asthenia—Clonazepam—epilepsy syndrome	0.000148	0.000486	CcSEcCtD
Apraclonidine—Rhinitis—Topiramate—epilepsy syndrome	0.000148	0.000485	CcSEcCtD
Apraclonidine—Headache—Fosphenytoin—epilepsy syndrome	0.000147	0.000484	CcSEcCtD
Apraclonidine—Haemorrhage—Topiramate—epilepsy syndrome	0.000147	0.000484	CcSEcCtD
Apraclonidine—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000147	0.000484	CcSEcCtD
Apraclonidine—Palpitations—Pregabalin—epilepsy syndrome	0.000147	0.000483	CcSEcCtD
Apraclonidine—Asthenia—Phenytoin—epilepsy syndrome	0.000147	0.000483	CcSEcCtD
Apraclonidine—Nausea—Midazolam—epilepsy syndrome	0.000147	0.000482	CcSEcCtD
Apraclonidine—Diarrhoea—Zonisamide—epilepsy syndrome	0.000146	0.000481	CcSEcCtD
Apraclonidine—Pharyngitis—Topiramate—epilepsy syndrome	0.000146	0.000481	CcSEcCtD
Apraclonidine—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000146	0.00048	CcSEcCtD
Apraclonidine—Pruritus—Clonazepam—epilepsy syndrome	0.000146	0.000479	CcSEcCtD
Apraclonidine—Vomiting—Vigabatrin—epilepsy syndrome	0.000146	0.000479	CcSEcCtD
Apraclonidine—Skin disorder—Valproic Acid—epilepsy syndrome	0.000146	0.000479	CcSEcCtD
Apraclonidine—Oedema peripheral—Topiramate—epilepsy syndrome	0.000145	0.000477	CcSEcCtD
Apraclonidine—Pruritus—Phenytoin—epilepsy syndrome	0.000145	0.000476	CcSEcCtD
Apraclonidine—Nausea—Levetiracetam—epilepsy syndrome	0.000145	0.000476	CcSEcCtD
Apraclonidine—Dizziness—Felbamate—epilepsy syndrome	0.000144	0.000475	CcSEcCtD
Apraclonidine—Dermatitis—Vigabatrin—epilepsy syndrome	0.000144	0.000475	CcSEcCtD
Apraclonidine—Pruritus—Oxcarbazepine—epilepsy syndrome	0.000144	0.000473	CcSEcCtD
Apraclonidine—Hypersensitivity—Carbamazepine—epilepsy syndrome	0.000144	0.000473	CcSEcCtD
Apraclonidine—Vision blurred—Gabapentin—epilepsy syndrome	0.000144	0.000472	CcSEcCtD
Apraclonidine—Headache—Vigabatrin—epilepsy syndrome	0.000144	0.000472	CcSEcCtD
Apraclonidine—Vomiting—Diazepam—epilepsy syndrome	0.000144	0.000472	CcSEcCtD
Apraclonidine—Dermatitis—Diazepam—epilepsy syndrome	0.000142	0.000467	CcSEcCtD
Apraclonidine—Visual impairment—Topiramate—epilepsy syndrome	0.000142	0.000467	CcSEcCtD
Apraclonidine—Myalgia—Pregabalin—epilepsy syndrome	0.000142	0.000465	CcSEcCtD
Apraclonidine—Chest pain—Pregabalin—epilepsy syndrome	0.000142	0.000465	CcSEcCtD
Apraclonidine—Ill-defined disorder—Gabapentin—epilepsy syndrome	0.000141	0.000465	CcSEcCtD
Apraclonidine—Dizziness—Zonisamide—epilepsy syndrome	0.000141	0.000465	CcSEcCtD
Apraclonidine—Headache—Diazepam—epilepsy syndrome	0.000141	0.000465	CcSEcCtD
Apraclonidine—Diarrhoea—Clonazepam—epilepsy syndrome	0.000141	0.000463	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000141	0.000462	CcSEcCtD
Apraclonidine—Asthenia—Carbamazepine—epilepsy syndrome	0.00014	0.000461	CcSEcCtD
Apraclonidine—Diarrhoea—Phenytoin—epilepsy syndrome	0.00014	0.00046	CcSEcCtD
Apraclonidine—Discomfort—Pregabalin—epilepsy syndrome	0.00014	0.00046	CcSEcCtD
Apraclonidine—Nausea—Fosphenytoin—epilepsy syndrome	0.00014	0.000459	CcSEcCtD
Apraclonidine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000139	0.000458	CcSEcCtD
Apraclonidine—Hypersensitivity—Lamotrigine—epilepsy syndrome	0.000139	0.000457	CcSEcCtD
Apraclonidine—Vomiting—Felbamate—epilepsy syndrome	0.000139	0.000456	CcSEcCtD
Apraclonidine—Dry mouth—Pregabalin—epilepsy syndrome	0.000138	0.000455	CcSEcCtD
Apraclonidine—Pruritus—Carbamazepine—epilepsy syndrome	0.000138	0.000454	CcSEcCtD
Apraclonidine—Eye disorder—Topiramate—epilepsy syndrome	0.000138	0.000452	CcSEcCtD
Apraclonidine—Dermatitis—Felbamate—epilepsy syndrome	0.000138	0.000452	CcSEcCtD
Apraclonidine—Malaise—Gabapentin—epilepsy syndrome	0.000137	0.000452	CcSEcCtD
Apraclonidine—Headache—Felbamate—epilepsy syndrome	0.000137	0.00045	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	0.000137	0.000449	CcSEcCtD
Apraclonidine—Syncope—Gabapentin—epilepsy syndrome	0.000137	0.000449	CcSEcCtD
Apraclonidine—Dizziness—Clonazepam—epilepsy syndrome	0.000136	0.000448	CcSEcCtD
Apraclonidine—Nausea—Vigabatrin—epilepsy syndrome	0.000136	0.000448	CcSEcCtD
Apraclonidine—Vomiting—Zonisamide—epilepsy syndrome	0.000136	0.000447	CcSEcCtD
Apraclonidine—Insomnia—Valproic Acid—epilepsy syndrome	0.000136	0.000446	CcSEcCtD
Apraclonidine—Oedema—Pregabalin—epilepsy syndrome	0.000136	0.000446	CcSEcCtD
Apraclonidine—Asthenia—Lamotrigine—epilepsy syndrome	0.000136	0.000445	CcSEcCtD
Apraclonidine—Dizziness—Phenytoin—epilepsy syndrome	0.000135	0.000445	CcSEcCtD
Apraclonidine—Infection—Pregabalin—epilepsy syndrome	0.000135	0.000443	CcSEcCtD
Apraclonidine—Paraesthesia—Valproic Acid—epilepsy syndrome	0.000135	0.000443	CcSEcCtD
Apraclonidine—Palpitations—Gabapentin—epilepsy syndrome	0.000135	0.000443	CcSEcCtD
Apraclonidine—Dermatitis—Zonisamide—epilepsy syndrome	0.000135	0.000443	CcSEcCtD
Apraclonidine—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000135	0.000443	CcSEcCtD
Apraclonidine—Nausea—Diazepam—epilepsy syndrome	0.000134	0.000441	CcSEcCtD
Apraclonidine—Headache—Zonisamide—epilepsy syndrome	0.000134	0.00044	CcSEcCtD
Apraclonidine—Dyspnoea—Valproic Acid—epilepsy syndrome	0.000134	0.00044	CcSEcCtD
Apraclonidine—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000134	0.000439	CcSEcCtD
Apraclonidine—Angiopathy—Topiramate—epilepsy syndrome	0.000134	0.000439	CcSEcCtD
Apraclonidine—Pruritus—Lamotrigine—epilepsy syndrome	0.000134	0.000439	CcSEcCtD
Apraclonidine—Somnolence—Valproic Acid—epilepsy syndrome	0.000133	0.000438	CcSEcCtD
Apraclonidine—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000133	0.000437	CcSEcCtD
Apraclonidine—Mediastinal disorder—Topiramate—epilepsy syndrome	0.000133	0.000436	CcSEcCtD
Apraclonidine—Skin disorder—Pregabalin—epilepsy syndrome	0.000132	0.000433	CcSEcCtD
Apraclonidine—Vomiting—Clonazepam—epilepsy syndrome	0.000131	0.000431	CcSEcCtD
Apraclonidine—Vomiting—Phenytoin—epilepsy syndrome	0.00013	0.000428	CcSEcCtD
Apraclonidine—Dermatitis—Clonazepam—epilepsy syndrome	0.00013	0.000427	CcSEcCtD
Apraclonidine—Chest pain—Gabapentin—epilepsy syndrome	0.00013	0.000426	CcSEcCtD
Apraclonidine—Myalgia—Gabapentin—epilepsy syndrome	0.00013	0.000426	CcSEcCtD
Apraclonidine—Nausea—Felbamate—epilepsy syndrome	0.00013	0.000426	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.00013	0.000426	CcSEcCtD
Apraclonidine—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000129	0.000425	CcSEcCtD
Apraclonidine—Fatigue—Valproic Acid—epilepsy syndrome	0.000129	0.000425	CcSEcCtD
Apraclonidine—Dizziness—Carbamazepine—epilepsy syndrome	0.000129	0.000425	CcSEcCtD
Apraclonidine—Diarrhoea—Lamotrigine—epilepsy syndrome	0.000129	0.000425	CcSEcCtD
Apraclonidine—Headache—Clonazepam—epilepsy syndrome	0.000129	0.000424	CcSEcCtD
Apraclonidine—Mental disorder—Topiramate—epilepsy syndrome	0.000129	0.000424	CcSEcCtD
Apraclonidine—Dermatitis—Phenytoin—epilepsy syndrome	0.000129	0.000424	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.000129	0.000424	CcSEcCtD
Apraclonidine—Pain—Valproic Acid—epilepsy syndrome	0.000128	0.000422	CcSEcCtD
Apraclonidine—Constipation—Valproic Acid—epilepsy syndrome	0.000128	0.000422	CcSEcCtD
Apraclonidine—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000128	0.000422	CcSEcCtD
Apraclonidine—Headache—Phenytoin—epilepsy syndrome	0.000128	0.000421	CcSEcCtD
Apraclonidine—Erythema—Topiramate—epilepsy syndrome	0.000128	0.000421	CcSEcCtD
Apraclonidine—Discomfort—Gabapentin—epilepsy syndrome	0.000128	0.000421	CcSEcCtD
Apraclonidine—Headache—Oxcarbazepine—epilepsy syndrome	0.000128	0.000419	CcSEcCtD
Apraclonidine—Nausea—Zonisamide—epilepsy syndrome	0.000127	0.000417	CcSEcCtD
Apraclonidine—Dry mouth—Gabapentin—epilepsy syndrome	0.000127	0.000417	CcSEcCtD
Apraclonidine—Tension—Topiramate—epilepsy syndrome	0.000126	0.000414	CcSEcCtD
Apraclonidine—Dysgeusia—Topiramate—epilepsy syndrome	0.000126	0.000413	CcSEcCtD
Apraclonidine—Dizziness—Lamotrigine—epilepsy syndrome	0.000125	0.00041	CcSEcCtD
Apraclonidine—Nervousness—Topiramate—epilepsy syndrome	0.000125	0.000409	CcSEcCtD
Apraclonidine—Oedema—Gabapentin—epilepsy syndrome	0.000124	0.000409	CcSEcCtD
Apraclonidine—Vomiting—Carbamazepine—epilepsy syndrome	0.000124	0.000408	CcSEcCtD
Apraclonidine—Feeling abnormal—Valproic Acid—epilepsy syndrome	0.000124	0.000406	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	0.000124	0.000406	CcSEcCtD
Apraclonidine—Infection—Gabapentin—epilepsy syndrome	0.000124	0.000406	CcSEcCtD
Apraclonidine—Dermatitis—Carbamazepine—epilepsy syndrome	0.000123	0.000405	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	0.000123	0.000403	CcSEcCtD
Apraclonidine—Insomnia—Pregabalin—epilepsy syndrome	0.000123	0.000403	CcSEcCtD
Apraclonidine—Nausea—Clonazepam—epilepsy syndrome	0.000122	0.000402	CcSEcCtD
Apraclonidine—Headache—Carbamazepine—epilepsy syndrome	0.000122	0.000402	CcSEcCtD
Apraclonidine—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000122	0.000401	CcSEcCtD
Apraclonidine—Paraesthesia—Pregabalin—epilepsy syndrome	0.000122	0.0004	CcSEcCtD
Apraclonidine—Nausea—Phenytoin—epilepsy syndrome	0.000122	0.0004	CcSEcCtD
Apraclonidine—Dyspnoea—Pregabalin—epilepsy syndrome	0.000121	0.000398	CcSEcCtD
Apraclonidine—Nausea—Oxcarbazepine—epilepsy syndrome	0.000121	0.000398	CcSEcCtD
Apraclonidine—Vision blurred—Topiramate—epilepsy syndrome	0.000121	0.000397	CcSEcCtD
Apraclonidine—Skin disorder—Gabapentin—epilepsy syndrome	0.000121	0.000397	CcSEcCtD
Apraclonidine—Somnolence—Pregabalin—epilepsy syndrome	0.000121	0.000396	CcSEcCtD
Apraclonidine—Vomiting—Lamotrigine—epilepsy syndrome	0.00012	0.000395	CcSEcCtD
Apraclonidine—Ill-defined disorder—Topiramate—epilepsy syndrome	0.000119	0.000391	CcSEcCtD
Apraclonidine—Dermatitis—Lamotrigine—epilepsy syndrome	0.000119	0.000391	CcSEcCtD
Apraclonidine—Abdominal pain—Valproic Acid—epilepsy syndrome	0.000119	0.00039	CcSEcCtD
Apraclonidine—Headache—Lamotrigine—epilepsy syndrome	0.000118	0.000389	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	0.000117	0.000385	CcSEcCtD
Apraclonidine—Fatigue—Pregabalin—epilepsy syndrome	0.000117	0.000384	CcSEcCtD
Apraclonidine—Nausea—Carbamazepine—epilepsy syndrome	0.000116	0.000381	CcSEcCtD
Apraclonidine—Constipation—Pregabalin—epilepsy syndrome	0.000116	0.000381	CcSEcCtD
Apraclonidine—Pain—Pregabalin—epilepsy syndrome	0.000116	0.000381	CcSEcCtD
Apraclonidine—ADRA1A—brainstem—epilepsy syndrome	0.000116	0.0591	CbGeAlD
Apraclonidine—Malaise—Topiramate—epilepsy syndrome	0.000116	0.00038	CcSEcCtD
Apraclonidine—Syncope—Topiramate—epilepsy syndrome	0.000115	0.000378	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	0.000113	0.000372	CcSEcCtD
Apraclonidine—Palpitations—Topiramate—epilepsy syndrome	0.000113	0.000372	CcSEcCtD
Apraclonidine—Insomnia—Gabapentin—epilepsy syndrome	0.000113	0.00037	CcSEcCtD
Apraclonidine—Nausea—Lamotrigine—epilepsy syndrome	0.000112	0.000369	CcSEcCtD
Apraclonidine—Feeling abnormal—Pregabalin—epilepsy syndrome	0.000112	0.000367	CcSEcCtD
Apraclonidine—Paraesthesia—Gabapentin—epilepsy syndrome	0.000112	0.000367	CcSEcCtD
Apraclonidine—ADRA1A—forebrain—epilepsy syndrome	0.000112	0.057	CbGeAlD
Apraclonidine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	0.000111	0.000365	CcSEcCtD
Apraclonidine—Dyspnoea—Gabapentin—epilepsy syndrome	0.000111	0.000365	CcSEcCtD
Apraclonidine—Somnolence—Gabapentin—epilepsy syndrome	0.000111	0.000363	CcSEcCtD
Apraclonidine—Hypersensitivity—Valproic Acid—epilepsy syndrome	0.000111	0.000363	CcSEcCtD
Apraclonidine—Chest pain—Topiramate—epilepsy syndrome	0.000109	0.000359	CcSEcCtD
Apraclonidine—Myalgia—Topiramate—epilepsy syndrome	0.000109	0.000359	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	0.000108	0.000356	CcSEcCtD
Apraclonidine—Discomfort—Topiramate—epilepsy syndrome	0.000108	0.000355	CcSEcCtD
Apraclonidine—Asthenia—Valproic Acid—epilepsy syndrome	0.000108	0.000354	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	0.000107	0.000353	CcSEcCtD
Apraclonidine—Fatigue—Gabapentin—epilepsy syndrome	0.000107	0.000352	CcSEcCtD
Apraclonidine—Abdominal pain—Pregabalin—epilepsy syndrome	0.000107	0.000352	CcSEcCtD
Apraclonidine—Dry mouth—Topiramate—epilepsy syndrome	0.000107	0.000351	CcSEcCtD
Apraclonidine—Constipation—Gabapentin—epilepsy syndrome	0.000106	0.00035	CcSEcCtD
Apraclonidine—Pain—Gabapentin—epilepsy syndrome	0.000106	0.00035	CcSEcCtD
Apraclonidine—Pruritus—Valproic Acid—epilepsy syndrome	0.000106	0.000349	CcSEcCtD
Apraclonidine—Oedema—Topiramate—epilepsy syndrome	0.000105	0.000344	CcSEcCtD
Apraclonidine—Infection—Topiramate—epilepsy syndrome	0.000104	0.000342	CcSEcCtD
Apraclonidine—Diarrhoea—Valproic Acid—epilepsy syndrome	0.000103	0.000337	CcSEcCtD
Apraclonidine—ADRA1A—telencephalon—epilepsy syndrome	0.000103	0.0525	CbGeAlD
Apraclonidine—Nervous system disorder—Topiramate—epilepsy syndrome	0.000103	0.000337	CcSEcCtD
Apraclonidine—Feeling abnormal—Gabapentin—epilepsy syndrome	0.000103	0.000337	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	0.000102	0.000334	CcSEcCtD
Apraclonidine—Skin disorder—Topiramate—epilepsy syndrome	0.000102	0.000334	CcSEcCtD
Apraclonidine—Hypersensitivity—Pregabalin—epilepsy syndrome	0.0001	0.000328	CcSEcCtD
Apraclonidine—Dizziness—Valproic Acid—epilepsy syndrome	9.93e-05	0.000326	CcSEcCtD
Apraclonidine—Abdominal pain—Gabapentin—epilepsy syndrome	9.84e-05	0.000323	CcSEcCtD
Apraclonidine—ADRA2C—telencephalon—epilepsy syndrome	9.79e-05	0.05	CbGeAlD
Apraclonidine—Asthenia—Pregabalin—epilepsy syndrome	9.74e-05	0.00032	CcSEcCtD
Apraclonidine—Pruritus—Pregabalin—epilepsy syndrome	9.6e-05	0.000315	CcSEcCtD
Apraclonidine—Vomiting—Valproic Acid—epilepsy syndrome	9.54e-05	0.000314	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	9.54e-05	0.000313	CcSEcCtD
Apraclonidine—Insomnia—Topiramate—epilepsy syndrome	9.47e-05	0.000311	CcSEcCtD
Apraclonidine—Dermatitis—Valproic Acid—epilepsy syndrome	9.45e-05	0.000311	CcSEcCtD
Apraclonidine—Headache—Valproic Acid—epilepsy syndrome	9.4e-05	0.000309	CcSEcCtD
Apraclonidine—Paraesthesia—Topiramate—epilepsy syndrome	9.4e-05	0.000309	CcSEcCtD
Apraclonidine—Dyspnoea—Topiramate—epilepsy syndrome	9.33e-05	0.000307	CcSEcCtD
Apraclonidine—Somnolence—Topiramate—epilepsy syndrome	9.31e-05	0.000306	CcSEcCtD
Apraclonidine—Diarrhoea—Pregabalin—epilepsy syndrome	9.28e-05	0.000305	CcSEcCtD
Apraclonidine—Hypersensitivity—Gabapentin—epilepsy syndrome	9.17e-05	0.000301	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	9.04e-05	0.000297	CcSEcCtD
Apraclonidine—Fatigue—Topiramate—epilepsy syndrome	9.03e-05	0.000297	CcSEcCtD
Apraclonidine—Dizziness—Pregabalin—epilepsy syndrome	8.97e-05	0.000295	CcSEcCtD
Apraclonidine—Constipation—Topiramate—epilepsy syndrome	8.95e-05	0.000294	CcSEcCtD
Apraclonidine—Pain—Topiramate—epilepsy syndrome	8.95e-05	0.000294	CcSEcCtD
Apraclonidine—Asthenia—Gabapentin—epilepsy syndrome	8.93e-05	0.000293	CcSEcCtD
Apraclonidine—Nausea—Valproic Acid—epilepsy syndrome	8.92e-05	0.000293	CcSEcCtD
Apraclonidine—Pruritus—Gabapentin—epilepsy syndrome	8.8e-05	0.000289	CcSEcCtD
Apraclonidine—Vomiting—Pregabalin—epilepsy syndrome	8.63e-05	0.000283	CcSEcCtD
Apraclonidine—Feeling abnormal—Topiramate—epilepsy syndrome	8.63e-05	0.000283	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Topiramate—epilepsy syndrome	8.56e-05	0.000281	CcSEcCtD
Apraclonidine—Dermatitis—Pregabalin—epilepsy syndrome	8.55e-05	0.000281	CcSEcCtD
Apraclonidine—Diarrhoea—Gabapentin—epilepsy syndrome	8.51e-05	0.00028	CcSEcCtD
Apraclonidine—Headache—Pregabalin—epilepsy syndrome	8.5e-05	0.000279	CcSEcCtD
Apraclonidine—ADRA2A—forebrain—epilepsy syndrome	8.49e-05	0.0434	CbGeAlD
Apraclonidine—Abdominal pain—Topiramate—epilepsy syndrome	8.28e-05	0.000272	CcSEcCtD
Apraclonidine—Dizziness—Gabapentin—epilepsy syndrome	8.23e-05	0.00027	CcSEcCtD
Apraclonidine—Nausea—Pregabalin—epilepsy syndrome	8.06e-05	0.000265	CcSEcCtD
Apraclonidine—Vomiting—Gabapentin—epilepsy syndrome	7.91e-05	0.00026	CcSEcCtD
Apraclonidine—Dermatitis—Gabapentin—epilepsy syndrome	7.84e-05	0.000258	CcSEcCtD
Apraclonidine—ADRA2A—telencephalon—epilepsy syndrome	7.81e-05	0.0399	CbGeAlD
Apraclonidine—Headache—Gabapentin—epilepsy syndrome	7.79e-05	0.000256	CcSEcCtD
Apraclonidine—Hypersensitivity—Topiramate—epilepsy syndrome	7.71e-05	0.000253	CcSEcCtD
Apraclonidine—ADRA2C—medulla oblongata—epilepsy syndrome	7.69e-05	0.0393	CbGeAlD
Apraclonidine—Asthenia—Topiramate—epilepsy syndrome	7.51e-05	0.000247	CcSEcCtD
Apraclonidine—Pruritus—Topiramate—epilepsy syndrome	7.41e-05	0.000243	CcSEcCtD
Apraclonidine—Nausea—Gabapentin—epilepsy syndrome	7.39e-05	0.000243	CcSEcCtD
Apraclonidine—Diarrhoea—Topiramate—epilepsy syndrome	7.16e-05	0.000235	CcSEcCtD
Apraclonidine—ADRA2C—midbrain—epilepsy syndrome	7.03e-05	0.0359	CbGeAlD
Apraclonidine—Dizziness—Topiramate—epilepsy syndrome	6.92e-05	0.000227	CcSEcCtD
Apraclonidine—ADRA2C—spinal cord—epilepsy syndrome	6.86e-05	0.035	CbGeAlD
Apraclonidine—Vomiting—Topiramate—epilepsy syndrome	6.66e-05	0.000219	CcSEcCtD
Apraclonidine—Dermatitis—Topiramate—epilepsy syndrome	6.59e-05	0.000217	CcSEcCtD
Apraclonidine—Headache—Topiramate—epilepsy syndrome	6.56e-05	0.000215	CcSEcCtD
Apraclonidine—ADRA1A—head—epilepsy syndrome	6.39e-05	0.0327	CbGeAlD
Apraclonidine—Nausea—Topiramate—epilepsy syndrome	6.22e-05	0.000204	CcSEcCtD
Apraclonidine—ADRA2A—medulla oblongata—epilepsy syndrome	6.14e-05	0.0313	CbGeAlD
Apraclonidine—ADRA2C—head—epilepsy syndrome	6.09e-05	0.0311	CbGeAlD
Apraclonidine—ADRA1A—nervous system—epilepsy syndrome	6.06e-05	0.031	CbGeAlD
Apraclonidine—ADRA1A—central nervous system—epilepsy syndrome	5.84e-05	0.0298	CbGeAlD
Apraclonidine—ADRA2C—nervous system—epilepsy syndrome	5.78e-05	0.0295	CbGeAlD
Apraclonidine—ADRA1A—cerebellum—epilepsy syndrome	5.71e-05	0.0291	CbGeAlD
Apraclonidine—ADRA2A—midbrain—epilepsy syndrome	5.61e-05	0.0286	CbGeAlD
Apraclonidine—ADRA2C—central nervous system—epilepsy syndrome	5.56e-05	0.0284	CbGeAlD
Apraclonidine—ADRA2A—spinal cord—epilepsy syndrome	5.47e-05	0.0279	CbGeAlD
Apraclonidine—ADRA2C—cerebellum—epilepsy syndrome	5.44e-05	0.0278	CbGeAlD
Apraclonidine—ADRA2A—head—epilepsy syndrome	4.86e-05	0.0248	CbGeAlD
Apraclonidine—ADRA1A—brain—epilepsy syndrome	4.63e-05	0.0237	CbGeAlD
Apraclonidine—ADRA2A—nervous system—epilepsy syndrome	4.61e-05	0.0235	CbGeAlD
Apraclonidine—ADRA2A—central nervous system—epilepsy syndrome	4.44e-05	0.0227	CbGeAlD
Apraclonidine—ADRA2C—brain—epilepsy syndrome	4.42e-05	0.0226	CbGeAlD
Apraclonidine—ADRA2A—cerebellum—epilepsy syndrome	4.34e-05	0.0222	CbGeAlD
Apraclonidine—ADRA2A—brain—epilepsy syndrome	3.52e-05	0.018	CbGeAlD
Apraclonidine—ADRA2C—Signaling Pathways—DUSP6—epilepsy syndrome	1.64e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JUNB—epilepsy syndrome	1.63e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CNR1—epilepsy syndrome	1.63e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PLCB1—epilepsy syndrome	1.62e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRA2A—epilepsy syndrome	1.62e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR5—epilepsy syndrome	1.61e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AGT—epilepsy syndrome	1.61e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PLAT—epilepsy syndrome	1.61e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CRH—epilepsy syndrome	1.6e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—OXT—epilepsy syndrome	1.6e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL3—epilepsy syndrome	1.6e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL2—epilepsy syndrome	1.6e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HSPB1—epilepsy syndrome	1.6e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR7—epilepsy syndrome	1.59e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—SRC—epilepsy syndrome	1.58e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR3—epilepsy syndrome	1.58e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—HTR2A—epilepsy syndrome	1.58e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR5—epilepsy syndrome	1.57e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—BCHE—epilepsy syndrome	1.56e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL12—epilepsy syndrome	1.55e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BDKRB2—epilepsy syndrome	1.55e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—POMC—epilepsy syndrome	1.55e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.55e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PRKCB—epilepsy syndrome	1.54e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HBEGF—epilepsy syndrome	1.54e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—VEGFA—epilepsy syndrome	1.54e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HTR2A—epilepsy syndrome	1.54e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6ST—epilepsy syndrome	1.54e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NPY—epilepsy syndrome	1.54e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ATP2A2—epilepsy syndrome	1.54e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CNR1—epilepsy syndrome	1.52e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JUNB—epilepsy syndrome	1.52e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PLCB1—epilepsy syndrome	1.52e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT3—epilepsy syndrome	1.52e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—HMOX1—epilepsy syndrome	1.51e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—POMC—epilepsy syndrome	1.51e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AGT—epilepsy syndrome	1.5e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SLC2A1—epilepsy syndrome	1.49e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CAT—epilepsy syndrome	1.49e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.49e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR7—epilepsy syndrome	1.49e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TSC1—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTK2B—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HSPB1—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL2—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL3—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CRH—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—OXT—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADAM10—epilepsy syndrome	1.48e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PLCB1—epilepsy syndrome	1.47e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL2—epilepsy syndrome	1.47e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TH—epilepsy syndrome	1.47e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR5—epilepsy syndrome	1.46e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AGT—epilepsy syndrome	1.46e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ABCB1—epilepsy syndrome	1.45e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NTRK2—epilepsy syndrome	1.44e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SST—epilepsy syndrome	1.44e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR2—epilepsy syndrome	1.44e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HBEGF—epilepsy syndrome	1.44e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HTR2A—epilepsy syndrome	1.43e-05	9.92e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DUSP6—epilepsy syndrome	1.43e-05	9.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT3—epilepsy syndrome	1.42e-05	9.82e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRA2A—epilepsy syndrome	1.41e-05	9.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—POMC—epilepsy syndrome	1.41e-05	9.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PLAT—epilepsy syndrome	1.41e-05	9.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—S100B—epilepsy syndrome	1.4e-05	9.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SOCS3—epilepsy syndrome	1.39e-05	9.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDC42—epilepsy syndrome	1.38e-05	9.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADAM10—epilepsy syndrome	1.38e-05	9.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.38e-05	9.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTK2B—epilepsy syndrome	1.38e-05	9.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TSC1—epilepsy syndrome	1.38e-05	9.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL2—epilepsy syndrome	1.38e-05	9.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AGT—epilepsy syndrome	1.36e-05	9.41e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BDKRB2—epilepsy syndrome	1.36e-05	9.4e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL12—epilepsy syndrome	1.36e-05	9.4e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—POMC—epilepsy syndrome	1.35e-05	9.39e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PRKCB—epilepsy syndrome	1.35e-05	9.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GPX1—epilepsy syndrome	1.35e-05	9.34e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6ST—epilepsy syndrome	1.35e-05	9.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SST—epilepsy syndrome	1.34e-05	9.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NTRK2—epilepsy syndrome	1.34e-05	9.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR2—epilepsy syndrome	1.34e-05	9.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AVP—epilepsy syndrome	1.34e-05	9.28e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JUNB—epilepsy syndrome	1.33e-05	9.23e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CNR1—epilepsy syndrome	1.33e-05	9.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DUSP6—epilepsy syndrome	1.33e-05	9.21e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PLCB1—epilepsy syndrome	1.33e-05	9.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—S100B—epilepsy syndrome	1.31e-05	9.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLAT—epilepsy syndrome	1.31e-05	9.06e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR7—epilepsy syndrome	1.3e-05	9.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SOCS3—epilepsy syndrome	1.3e-05	8.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDC42—epilepsy syndrome	1.29e-05	8.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SRC—epilepsy syndrome	1.28e-05	8.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HES1—epilepsy syndrome	1.27e-05	8.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HBEGF—epilepsy syndrome	1.26e-05	8.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL12—epilepsy syndrome	1.26e-05	8.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BDKRB2—epilepsy syndrome	1.26e-05	8.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—POMC—epilepsy syndrome	1.26e-05	8.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	1.25e-05	8.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—epilepsy syndrome	1.25e-05	8.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AVP—epilepsy syndrome	1.25e-05	8.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	1.25e-05	8.66e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT3—epilepsy syndrome	1.24e-05	8.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JUNB—epilepsy syndrome	1.24e-05	8.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CNR1—epilepsy syndrome	1.24e-05	8.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	1.23e-05	8.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FYN—epilepsy syndrome	1.23e-05	8.54e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—POMC—epilepsy syndrome	1.23e-05	8.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—H2AFX—epilepsy syndrome	1.23e-05	8.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	1.23e-05	8.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MEF2C—epilepsy syndrome	1.22e-05	8.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAT—epilepsy syndrome	1.21e-05	8.39e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADAM10—epilepsy syndrome	1.21e-05	8.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	1.21e-05	8.37e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL2—epilepsy syndrome	1.2e-05	8.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—YWHAZ—epilepsy syndrome	1.18e-05	8.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HES1—epilepsy syndrome	1.18e-05	8.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AGT—epilepsy syndrome	1.18e-05	8.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	1.18e-05	8.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	1.17e-05	8.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NGF—epilepsy syndrome	1.17e-05	8.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOE—epilepsy syndrome	1.16e-05	8.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FYN—epilepsy syndrome	1.15e-05	7.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	1.15e-05	7.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—H2AFX—epilepsy syndrome	1.15e-05	7.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MEF2C—epilepsy syndrome	1.14e-05	7.93e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—S100B—epilepsy syndrome	1.14e-05	7.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	1.14e-05	7.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR5—epilepsy syndrome	1.14e-05	7.89e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SOCS3—epilepsy syndrome	1.13e-05	7.85e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDC42—epilepsy syndrome	1.13e-05	7.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	1.12e-05	7.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	1.12e-05	7.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR2A—epilepsy syndrome	1.11e-05	7.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—YWHAZ—epilepsy syndrome	1.11e-05	7.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX1—epilepsy syndrome	1.09e-05	7.58e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AVP—epilepsy syndrome	1.09e-05	7.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NGF—epilepsy syndrome	1.09e-05	7.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR5—epilepsy syndrome	1.06e-05	7.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	1.06e-05	7.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TSC2—epilepsy syndrome	1.06e-05	7.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGT—epilepsy syndrome	1.06e-05	7.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT1—epilepsy syndrome	1.05e-05	7.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	1.05e-05	7.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	1.05e-05	7.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—epilepsy syndrome	1.04e-05	7.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—epilepsy syndrome	1.04e-05	7.18e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HES1—epilepsy syndrome	1.03e-05	7.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	1.02e-05	7.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KDR—epilepsy syndrome	1.01e-05	7.03e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FYN—epilepsy syndrome	1.01e-05	6.97e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—H2AFX—epilepsy syndrome	1e-05	6.95e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MEF2C—epilepsy syndrome	1e-05	6.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—epilepsy syndrome	9.94e-06	6.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TSC2—epilepsy syndrome	9.89e-06	6.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGT—epilepsy syndrome	9.88e-06	6.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—epilepsy syndrome	9.83e-06	6.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCB—epilepsy syndrome	9.77e-06	6.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6ST—epilepsy syndrome	9.73e-06	6.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—epilepsy syndrome	9.68e-06	6.71e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—YWHAZ—epilepsy syndrome	9.67e-06	6.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	9.61e-06	6.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGT—epilepsy syndrome	9.59e-06	6.65e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NGF—epilepsy syndrome	9.56e-06	6.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—epilepsy syndrome	9.48e-06	6.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—epilepsy syndrome	9.4e-06	6.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	9.34e-06	6.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	9.31e-06	6.45e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR5—epilepsy syndrome	9.3e-06	6.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	9.29e-06	6.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCB—epilepsy syndrome	9.13e-06	6.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—epilepsy syndrome	9.1e-06	6.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6ST—epilepsy syndrome	9.09e-06	6.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—epilepsy syndrome	9.06e-06	6.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	8.98e-06	6.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—epilepsy syndrome	8.9e-06	6.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	8.88e-06	6.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—epilepsy syndrome	8.71e-06	6.04e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TSC2—epilepsy syndrome	8.64e-06	5.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	8.64e-06	5.99e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGT—epilepsy syndrome	8.63e-06	5.98e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—epilepsy syndrome	8.46e-06	5.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	8.45e-06	5.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—epilepsy syndrome	8.31e-06	5.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—epilepsy syndrome	8.29e-06	5.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—epilepsy syndrome	8.13e-06	5.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—epilepsy syndrome	8.07e-06	5.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	8.03e-06	5.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	8.02e-06	5.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	7.98e-06	5.53e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCB—epilepsy syndrome	7.98e-06	5.53e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6ST—epilepsy syndrome	7.95e-06	5.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—epilepsy syndrome	7.93e-06	5.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGF2—epilepsy syndrome	7.87e-06	5.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	7.86e-06	5.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	7.7e-06	5.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	7.41e-06	5.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	7.38e-06	5.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—epilepsy syndrome	7.36e-06	5.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGF2—epilepsy syndrome	7.35e-06	5.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RELA—epilepsy syndrome	7.31e-06	5.06e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—epilepsy syndrome	7.27e-06	5.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTOR—epilepsy syndrome	7.16e-06	4.97e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—epilepsy syndrome	7.11e-06	4.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RELA—epilepsy syndrome	6.82e-06	4.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	6.75e-06	4.68e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTOR—epilepsy syndrome	6.69e-06	4.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—epilepsy syndrome	6.65e-06	4.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	6.61e-06	4.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—epilepsy syndrome	6.59e-06	4.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	6.44e-06	4.46e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF2—epilepsy syndrome	6.43e-06	4.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JUN—epilepsy syndrome	6.4e-06	4.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—epilepsy syndrome	6.23e-06	4.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—epilepsy syndrome	6.21e-06	4.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—epilepsy syndrome	6.15e-06	4.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—epilepsy syndrome	6.04e-06	4.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JUN—epilepsy syndrome	5.98e-06	4.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	5.97e-06	4.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RELA—epilepsy syndrome	5.97e-06	4.13e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTOR—epilepsy syndrome	5.85e-06	4.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—epilepsy syndrome	5.82e-06	4.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—epilepsy syndrome	5.74e-06	3.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—epilepsy syndrome	5.64e-06	3.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—epilepsy syndrome	5.59e-06	3.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	5.54e-06	3.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	5.44e-06	3.77e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—epilepsy syndrome	5.43e-06	3.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—epilepsy syndrome	5.38e-06	3.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—epilepsy syndrome	5.36e-06	3.72e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JUN—epilepsy syndrome	5.23e-06	3.62e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—epilepsy syndrome	5.22e-06	3.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—epilepsy syndrome	5.08e-06	3.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	5.05e-06	3.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	5e-06	3.47e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—epilepsy syndrome	4.93e-06	3.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	4.86e-06	3.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	4.72e-06	3.27e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—epilepsy syndrome	4.69e-06	3.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	4.58e-06	3.18e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—epilepsy syndrome	4.57e-06	3.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	4.36e-06	3.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	4.24e-06	2.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—epilepsy syndrome	3.99e-06	2.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—epilepsy syndrome	3.57e-06	2.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—epilepsy syndrome	3.33e-06	2.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—epilepsy syndrome	3.24e-06	2.24e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—epilepsy syndrome	2.91e-06	2.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	2.71e-06	1.88e-05	CbGpPWpGaD
